Dewin Reproductive Media (Dewin Fertilization Medium [with HSA and without HSA] and Dewin Cleavage Medium [with HSA and without HSA])

K212426 · Donnevie Medical Technology (Shanghai) Co. , Ltd. · MQL · Jun 16, 2022 · Obstetrics/Gynecology

Device Facts

Record IDK212426
Device NameDewin Reproductive Media (Dewin Fertilization Medium [with HSA and without HSA] and Dewin Cleavage Medium [with HSA and without HSA])
ApplicantDonnevie Medical Technology (Shanghai) Co. , Ltd.
Product CodeMQL · Obstetrics/Gynecology
Decision DateJun 16, 2022
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 884.6180
Device ClassClass 2

Intended Use

Dewin Fertilization Medium is intended for use during in vitro fertilization (IVF) procedures and culture to the two pronuclei (zygote) stage of development. Dewin Fertilization Medium is also intended for washing and handling sperm and collected oocytes after aspiration prior to IVF procedures. Dewin Fertilization Medium is not intended for use in intrauterine insemination procedures. Dewin Cleavage Medium is intended for culture of embryos from the two pronuclei (zygote) stage to the 8-cell stage of embryo development. Dewin Cleavage Medium is also intended for use in the transfer of cleavage stage embryos into the uterine cavity.

Device Story

Dewin Reproductive Media consists of two liquid formulations: Fertilization Medium and Cleavage Medium. Used in IVF laboratories by embryologists to support gamete and embryo development. Fertilization Medium facilitates sperm/oocyte washing and culture to the zygote stage. Cleavage Medium supports embryo development from zygote to 8-cell stage and facilitates embryo transfer. Media contain salts, energy substrates, antioxidants, nutrients, amino acids, EDTA, gentamicin, and phenol red; available with or without Human Serum Albumin (HSA). Provided in 25 mL or 50 mL glass bottles. Aseptically filtered and single-use. Benefits include providing a controlled environment for fertilization and embryo development, increasing the likelihood of successful IVF outcomes.

Clinical Evidence

Bench testing only. Includes biocompatibility (cytotoxicity, sensitization, intracutaneous reactivity per ISO 10993), sterile filtration/aseptic fill validation, shelf-life stability (accelerated aging per ASTM F1980-16), Mouse Embryo Assay (MEA) showing ≥80% blastocyst development, and sterility/endotoxin testing.

Technological Characteristics

Liquid media containing salts, energy substrates, antioxidants, nutrients, amino acids, EDTA, gentamicin, and phenol red. Aseptically filtered. pH 7.2-7.5; osmolality 260-295 mOsm/kg; endotoxin < 0.25 EU/mL. Provided in 25/50 mL glass bottles with polypropylene caps. Storage 2-8°C. Shelf-life 4 months. Sterility per USP <71>.

Indications for Use

Indicated for use in IVF procedures, including sperm and oocyte washing/handling, culture to the zygote stage, embryo culture to the 8-cell stage, and embryo transfer into the uterine cavity. Not for intrauterine insemination.

Regulatory Classification

Identification

Reproductive media and supplement are products that are used for assisted reproduction procedures. Media include liquid and powder versions of various substances that come in direct physical contact with human gametes or embryos (including water, acid solutions used to treat gametes or embryos, rinsing solutions, sperm separation media, supplements, or oil used to cover the media) for the purposes of preparation, maintenance, transfer or storage. Supplements are specific reagents added to media to enhance specific properties of the media (e.g., proteins, sera, antibiotics, etc.).

Special Controls

*Classification.* Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing). The device, when it is phosphate-buffered saline used for washing, and short-term handling and manipulation of gametes and embryos; culture oil used as an overlay for culture media containing gametes and embryos; and water for assisted reproduction applications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. June 16, 2022 DonneVie Medical Technology (Shanghai) Co. Ltd. % Stuart R. Goldman Senior Regulatory Consultant. RA/OA Emergo Global Consulting, LLC 2500 Bee Cave Road, Building 1, Suite 300 Austin, TX 78746 Re: K212426 > Trade/Device Name: Dewin Reproductive Media (Dewin Fertilization Medium [with HSA and without HSA] and Dewin Cleavage Medium [with HSA and without HSA]) Regulation Number: 21 CFR§ 884.6180 Regulation Name: Reproductive Media and Supplements Regulatory Class: II Product Code: MOL Dated: May 10, 2022 Received: May 17, 2022 Dear Stuart R. Goldman: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatoryinformation/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, For Monica D. Garcia, Ph.D. Assistant Director DHT3B: Division of Reproductive. Gynecology and Urology Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## Indications for Use 510(k) Number (if known) K212426 #### Device Name Dewin Reproductive Media (Dewin Fertilization [with HSA and without HSA] and Dewin Cleavage Medium [with HSA and without HSA]) #### Indications for Use (Describe) Dewin Reproductive Media consists of Dewin Fertilization (with HSA and without HSA) and Dewin Cleavage Medium (with HSA and without HSA). The indications for use for the Dewin Fertilization Medium and Dewin Cleavage Medium are as follows: Dewin Fertilization Medium is intended for use during in vitro fertilization (IVF) procedures and culture to the two pronuclei (zygote) stage of development. Dewin Fertilization Medium is also intended for washing sperm and collected oocytes after aspiration prior to IVF procedures. Dewin Fertilization Medium is not intended for use in intrauterine insemination procedures. Dewin Cleavage Medium is intended for culture of embryos from the two pronuclei (zygote) stage of embryo development. Dewin Cleavage Medium is also intended for use in the transfer of cleavage stage embryos into the uterine cavity. | Type of Use (Select one or both, as applicable) | | |------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------| | <span style="font-size: 10pt;"> <span style="text-decoration: line-through;"> </span> Prescription Use (Part 21 CFR 801 Subpart D) </span> | <span style="font-size: 10pt;"> Over-The-Counter Use (21 CFR 801 Subpart C) </span> | #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ ## 510(k) Summary # Dewin Reproductive Media (Dewin Fertilization Medium [with HSA and without HSA], Dewin Cleavage Medium [with HSA and without HSA]) K212426 ## 1. Sponsor Information DonneVie Medical Technology (Shanghai) Co. Ltd. Suite 201, Bld. 1, 138 Xinjun Ring Minhang District, Shanghai, 201114, China Contact: Hannah Hang Yin Phone: +86 21 34781568 Title: CEO #### 2. Correspondent Information Emergo Global Consulting, LLC 2500 Bee Cave Road Building 1, Suite 300 Austin, TX 78746 Office Phone: (512) 327-9997 Email: LST.AUS.ProjectManagement@ul.com Contact: Stuart R. Goldman Title: Senior Regulatory Consultant, RA/QA #### 3. Date Prepared June 15, 2022 #### 4. Device Identification | Trade/Proprietary Name: | Dewin Reproductive Media (Dewin Fertilization Medium [with HSA and<br>without HSA], and Dewin Cleavage Medium [with HSA and without HSA]) | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------| | Common/Usual Name: | Reproductive Media | | Regulation Name: | Reproductive media and supplements | | Regulation Number: | 884.6180 | | Product Code: | MQL (Media, Reproductive) | | Class: | Class II | #### 5. Legally Marketed Predicate Device(s) Device name: Sydney IVF Fertilization Medium, Sydney IVF Cleavage Medium 510(k) number: K153290 Manufacturer: William A. Cook Australia Pty, Ltd. This predicate device has not been subject to a design-related recall. {4}------------------------------------------------ #### 6. Device Description Dewin Reproductive Media includes two products (Dewin Fertilization and Dewin Cleavage Medium). Dewin Fertilization Medium is intended for use in washing sperm and oocytes for use in in IVF procedures. Dewin Cleavage Medium, is intended for use in culturing embryos from the zygote stage to the 8-cell stage of development and can also be used for embryo transfer procedures. Dewin Reproductive Media are comprised of salts, energy substrates, anti-oxidant, nutrient supplements, amino acids, EDTA, gentamicin, and phenol red. Dewin Reproductive Media are offered with and without Human Serum Albumin (HSA). The Dewin Reproductive Media are aseptically filtered and filled into glass bottles with polypropylene caps. The devices are provided in 25 mL and 50 mL volumes. Dewin Reproductive Media have a fourmonth shelf-life when stored as recommended and are for single-use only. #### 7. Indications for Use Dewin Reproductive Media consists of Dewin Fertilization Medium (with HSA and without HSA) and Dewin Cleavage Medium (with HSA and without HSA). The indications for use for the Dewin Fertilization Medium and Dewin Cleavage Medium are as follows: Dewin Fertilization Medium is intended for use during vitro fertilization (IVF) procedures and culture to the two pronuclei (zygote) stage of development. Dewin Fertilization Medium is also intended for washing and handling sperm and collected oocytes after aspiration prior to IVF procedures. Dewin Fertilization Medium is not intended for use in intrauterine insemination procedures. Dewin Cleavage Medium is intended for culture of embryos from the two pronuclei (zygote) stage to the 8-cell stage of embryo development. Dewin Cleavage Medium is also intended for use in the transfer of cleavage stage embryos into the uterine cavity. - 8. Comparison of intended use and technological characteristics of the subject and predicate devices A comparison of the intended use and technological characteristics of the subject device and the predicate device is shown in the table below: | | Dewin Reproductive Media – K212426<br>(Subject Device) | Cook Sydney IVF<br>Media<br>- K153290<br>(Predicate Device) | Discussion | |-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Manufacturer | DonneVie Medical Technology<br>(Shanghai) Co. Ltd. | William A. Cook<br>Australia Pty, Ltd. | | | Product Code | MQL | MQL | | | Regulation<br>Number | 884.6180 | 884.6180 | | | Class | Class II | Class II | | | Indications<br>for Use | Dewin Reproductive Media consists of<br>Dewin Fertilization Medium (with HSA<br>and without HSA) and Dewin Cleavage<br>Medium (with HSA and without HSA). | Sydney IVF<br>Fertilization Medium<br>is intended for use<br>during in vitro | There are differences in thefor the subject and predicate<br>devices; however, the | | | The indications for use for the Dewin<br>Fertilization Medium and Dewin<br>Cleavage Medium are as follows:<br>Dewin Fertilization Medium is intended<br>for use during vitro fertilization (IVF)<br>procedures and culture to the two<br>pronuclei (zygote) stage of<br>development. Dewin Fertilization<br>Medium is also intended for washing<br>and handling sperm and collected<br>oocytes after aspiration prior to IVF<br>procedures. Dewin Fertilization Medium<br>is not intended for use in intrauterine<br>insemination procedures.<br>Dewin Cleavage Medium is intended for<br>culture of embryos from the two<br>pronuclei (zygote) stage to the 8-cell<br>stage of embryo development. Dewin | procedures for<br>insemination and<br>incubation of oocytes.<br>Sydney IVF Cleavage<br>Medium is intended<br>for use during in vitro<br>fertilization<br>procedures for culture<br>and transfer of<br>cleavage stage<br>embryos. | intended uses of the subject<br>and predicate devices are the<br>same. Therefore, they have<br>the same intended use. | | | Cleavage Medium is also intended for<br>use in the transfer of cleavage stage<br>embryos into the uterine cavity. | | | | Conditions of<br>Use | Rx Only | Rx Only | Same | | Device<br>Materials | Salts, energy substrates, anti-oxidant,<br>nutrient supplements, amino acids,<br>EDTA, gentamicin, and phenol red. It is<br>offered with and without HSA. | Salts, energy<br>substrates, buffer,<br>anti-oxidant, nutrient<br>supplements, amino<br>acids, antibiotic,<br>protein | Different: The formulations of<br>the subject and predicate<br>devices include the same<br>types of chemical<br>constituents; however, the<br>formulations are not the<br>same. Differences in device<br>formulations do not raise<br>different questions of safety<br>and effectiveness (S&E). | | Volume | 25, 50 mL | 20, 50, 100 mL | Different: The subject and<br>predicate devices are provided<br>in different volumes.<br>Differences in volumes do not | | | | | raise different questions of<br>S&E. | | Aseptically<br>Filtered | Yes | Yes | Same | | Single-Use | Yes | Yes | Same | | Storage<br>Condition | 2 – 8°C | 2 – 8°C | Same | | Shelf-Life | 4 months | 20 weeks | Different: The subject device<br>has a shorter shelf-life than<br>the predicate device.<br>Differences in shelf-life do not<br>raise different questions of<br>S&E. | | pH | 7.2-7.5 | 7.5 - 7.8 | Different: The subject device<br>has a lower pH range than the<br>predicate device. This<br>difference in pH range does<br>not raise different questions of<br>S&E. | | Osmolality | 260-295 mOsm/kg | 285-295 mOsm/kg | Different: The subject device<br>has a wider osmolality range<br>than the predicate device. This<br>difference in osmolality does<br>not raise different questions of<br>S&E. | | Sterility | No microbial growth | No microbial growth | Same | | Endotoxin | < 0.25 EU/mL | < 0.4 EU/mL | Different: The subject device<br>has a lower endotoxin<br>specification than the<br>predicate device. This<br>difference does not raise<br>different questions of S&E. | | MEA | One-cell system: ≥80% embryos<br>developed to expanded blastocyst at 96<br>hours after 24-hour exposure to Dewin<br>Fertilization Medium<br>One-cell system: ≥80% embryos<br>developed to expanded blastocyst at 96 | 2-Cell MEA: ≥ 80%<br>expanded blastocyst<br>at 72 hours | Different: There are<br>differences in the type of MEA<br>testing conducted. This<br>difference in MEA method<br>does not raise different<br>questions of S&E, as both<br>methods are acceptable to | | | hours after 48-hour exposure to Dewin<br>Cleavage Medium | support an assisted<br>reproduction media device. | | {5}------------------------------------------------ {6}------------------------------------------------ {7}------------------------------------------------ As shown in the table above, there are differences in the indications for use statements and technological features of the subject and predicate devices. However, as stated in the table, the differences in indications for use do not represent a new intended use and the differences in technological features do not raise different questions of safety and effectiveness. ## 9. Non-Clinical Performance Testing To demonstrate safety and effectiveness of Dewin Reproductive Media and to show substantial equivalence to the predicate device, DonneVie Medical Technology completed the following non-clinical tests. Results confirm that the design inputs and performance specifications for the device are met. - . Biocompatibility testing was conducted in support of the Dewin Cleavage Medium that will have direct contact with the patient during embryo transfer procedures. Testing was conducted in accordance with the 2020 FDA guidance Use of International Standard ISO 10993-1, Biological Evaluation of Medical Devices – Part 1: Evaluation and testing within a risk management process. Testing included: - l Cytotoxicity testing per ISO 10993-5:2009 - । Sensitization testing per ISO 10993-10:2010 - -Intracutaneous Reactivity per ISO 10993-10:2010 The testing demonstrated the Dewin Cleavage Medium formulations to be non-cytotoxic, nonsensitizing, and non-irritating. - . Sterile filtration and aseptic fill validation, per ISO 13408-1:2008 and ISO 13408-2:2018. - . Shelf-life testing was conducted to support the 4-month shelf-life for both products through demonstration that the product specifications (shown below) were met at time 0 and after accelerated aging in accordance with ASTM F1980-16: - -Appearance: Clear, particle-free - pH, per USP <791>: 7.2–7.5 - -Osmolality, per USP<785>: 260–295 mOsm/kg - -Endotoxin, per USP <85>: < 0.25 EU/mL - -MEA testing, in accordance with the 2021 FDA guidance Mouse Embryo Assay for Assisted Reproduction Technology Devices: - . Dewin Fertilization Medium: One-cell system: ≥80% embryos developed to expanded blastocyst at 96 hours after 24-hour exposure to Dewin Fertilization Medium - . Dewin Cleavage Medium: One-cell system: ≥80% embryos developed to expanded blastocyst at 96 hours after 48-hour exposure to Dewin Cleavage Medium - -Sterility, per USP <71>: No microbial growth - Transportation testing per ASTM D4169-16 ● {8}------------------------------------------------ ## 10. Statement of Substantial Equivalence The results of the performance testing described above demonstrate that the subject media products are as safe and effective as the predicate devices and support a determination of substantial equivalence.
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%